Drug repurposing screens identify chemical entities for the development of COVID-19 interventions
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug repurposing screens identify chemical entities for the development of COVID-19 interventions
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-06-03
DOI
10.1038/s41467-021-23328-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
- (2021) Angela Wahl et al. NATURE
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
- (2020) Emmie de Wit et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
- (2020) Timothy P. Sheahan et al. Science Translational Medicine
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19
- (2020) Wesley H. Self et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
- (2020) Robert M. Cox et al. Nature Microbiology
- Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial
- (2019) Zachary W. Veitch et al. BRITISH JOURNAL OF CANCER
- Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
- (2019) Mart Toots et al. Science Translational Medicine
- Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways
- (2019) Wanyu Dong et al. ANTIVIRAL RESEARCH
- The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis
- (2018) Jeff Janes et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antiviral activity of cationic amphiphilic drugs
- (2017) Cristiano Salata et al. Expert Review of Anti-Infective Therapy
- The Reactome Pathway Knowledgebase
- (2017) Antonio Fabregat et al. NUCLEIC ACIDS RESEARCH
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
- (2017) Timothy P. Sheahan et al. Science Translational Medicine
- GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo- and Paramyxoviruses
- (2017) Michael K. Lo et al. Scientific Reports
- Safety, pharmacokinetics, and pharmacodynamics of avoralstat, an oral plasma kallikrein inhibitor: phase 1 study
- (2016) M. Cornpropst et al. ALLERGY
- Emerging connections between RNA and autophagy
- (2016) Lisa B. Frankel et al. Autophagy
- A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach
- (2015) J Snoeys et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
- (2015) Bhagwan Yadav et al. Computational and Structural Biotechnology Journal
- A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
- (2012) D. S. Hong et al. CLINICAL CANCER RESEARCH
- Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients
- (2009) Henk W. Reesink et al. GASTROENTEROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started